Applications of FSC in the regulation of menstrual function in women

Danielyan T. Yu., gynecologist of the highest category, MD, chief physician of Medical Studio LLC, Perm
Danielyan N. A., dermatovenerologist, Medical Studio LLC, Perm

Relevance of the problem. The menstrual cycle is a complex biological process provided for by nature itself. Menstrual dysfunction and accompanying hormonal problems are one of the main causes of gynecological morbidity.

In the second half of the 20th century, there was a significant revision of the role of women in society and the family, and views on her health also changed. It is assumed that such changes in the function of the reproductive system, such as rare pregnancies, frequent abortions, lack of lactation, are accompanied by significant changes in hormonal status and explain the increase in the number of gynecological diseases such as menstrual dysfunction, adenomyosis, uterine fibroids, endometrial hyperplastic processes, etc.

In the structure of general gynecological morbidity, menstrual cycle disorders range from 15 to 53%. Menstrual dysfunction is accompanied by infertility and changes in body weight, diseases of the mammary glands, the development of psychoneurological disorders, menopausal and cardiovascular changes, and the development of osteoporosis. Taken together, all these problems significantly affect a woman’s quality of life.

Recently, worldwide interest in studying the problems and correction of menstrual dysfunction has increased significantly. The results of numerous studies indicate that when menstrual function is disrupted, the basic algorithm for the functioning of the reproductive system changes (disturbance in the cyclicity of sex hormone secretion).

Prevention and treatment of menstrual dysfunction should begin in the early stages, before the formation of female hormonal-dependent diseases.

Pharmacotherapy with steroid hormones is the main method of treatment in practical medicine and has an ambiguous effect on the woman’s body. All this dictates the need to find effective and safe methods for treating menstrual dysfunction in women.

There is a solution, since at the present stage, functional state correctors that have a complex effect on the most important organs and systems of the human body deserve special attention.

Purpose of the study. To evaluate the clinical effectiveness of the combined effects of CPS in patients with menstrual dysfunction.

Object and methods of the study. To carry out the study, an “Observation Card” was developed, which contained the criteria for inclusion in the study, general information about the patient, complaints and clinical symptoms, medical history, criteria for diagnosing the disease, treatment regimen and indicators of the clinical effectiveness of FSC.

The criterion for inclusion in the study was menstrual dysfunction in women of reproductive age, such as opsomenorrhea, against the background of anovulatory menstrual cycles and luteal phase insufficiency.

During the observation process, 63 patients were divided into two groups, depending on the treatment methods used. In the main group (42 people), a complex course of basic therapy was prescribed with the inclusion of functional state correctors (without the use of hormonal drugs). In the comparison group, patients (21 people) received hormonal drug therapy.

When assessing the initial status and effectiveness of the treatment courses, the following research methods were used:

• Relief of clinical symptoms of the disease
• Ultrasound monitoring of the state of the endometrium and ovarian folliculogenesis on days 10-12 and 20-22 of the menstrual cycle (performed for the purpose of dynamic monitoring of the restoration of the echographic picture of the endometrium and the presence of a dominant follicle during the periovulatory period of the menstrual cycle)
• Dynamics of changes in indicators of an immunohistochemical study of the state of the endometrium (pipeline test), performed on days 22-24 of the menstrual cycle

The average age of the women examined was 28.4 +/- 2.5 years. The groups did not differ in basic demographic indicators, heredity and physical status.

Complaints associated with menstrual irregularities were observed in all women and did not differ significantly between groups.

Patients most often complained of painful menstruation.

Irregularities in the duration of the menstrual cycle varied from day to day. Longer menstrual cycle disturbances were recorded only in patients with anovulatory ovarian dysfunction.

Anovulatory ovarian dysfunction during initial monitoring was diagnosed in 11 (17%) women (5 people and 6 people in groups 1 and 2, respectively).

Insufficiency of the luteal phase of the ovarian cycle (hypoluteism) was observed in 52 (82.5%) women (37 people and 15 people in the 1st and 2nd groups, respectively).

According to ultrasound data, all examined patients had impaired folliculogenesis in the ovaries and the absence of a dominant follicle during the periovulatory period.

Indicators of immunohistochemical study of the endometrium showed the presence of only proliferative processes and disruption of the endometrial receptor apparatus on days 20-22 of the cycle in 54 (85.7%) women (37 people and 17 people in the 1st and 2nd groups, respectively).

Treatment methods:

• Methodology for using FSC in women with menstrual dysfunction
• Take structured water using FSC in the amount of 30 ml per 1 kg of body weight per day
• Water procedures with FSC-structured water
• Restoring the body’s energy state by pumping the musculoskeletal system and energy centers of the body
• Wear the FSC on the problem area, periodically changing the location
• Impact of FSC on biologically active points of the body (BAP)

Method of using FSC on biologically active points of the body (BAP). The effect of FSC on BAP was carried out taking into account the cyclic influence of the autonomic nervous system (ANS) on the regulation of the menstrual cycle. This technique consists of using tonic points, supporting points, consent points and lo-points located on the yin meridians (yin) in the follicular phase of the menstrual cycle, and the use of BAT of the yang meridians (yang) in the luteal phase of the cycle. Local impact points were also used.

The procedure was carried out from the 1st to the 14th day of the menstrual cycle using BAPs of Yin meridians, from the 15th to 28th days BAPs of Yang meridians were used. Ultrasound monitoring of follicle development and identification of the dominant follicle was carried out in order to diagnose expected or accomplished ovulation and the condition of the endometrium.

Tab. 1. Application of FSC depending on the phase of the menstrual cycle and time of day in case of menstrual dysfunction.

In the case of ovarian dysfunction of central origin such as anovulation with menstrual dysfunction such as opsomenorea, the following methods of using FSC are recommended:

• FSC No. 2 – under the back of the head and FSC No. 3/8 – on the area between the eyebrows (5-10 minutes per day)
• FSC No. 13/15 – on the area between the eyebrows
• Pumping up the “bonnet” using several FSCs of the “blue” series

Results. An assessment of the clinical characteristics of the menstrual cycle and complaints made by patients 3 months after the start of therapy showed the following results.

• Complaints of opsomenorea persisted in 15 patients (23.8% - 11 people and 4 people in groups 1 and 2, respectively)
• The regularity of the menstrual rhythm was noted by 48 women (76.1% - 32 people and 16 people. in the 1st and 2nd groups, respectively), which demonstrates the comparable effectiveness of complex therapy with the inclusion of FSC for this symptom, as well as an advantage over drug therapy
• All patients of the main group (with FSC) noted subjective improvement, while in the comparison group only 4 out of 21 patients noted improvement, which indirectly reflects the greater potential of the influence of FSC on the general condition of the body of women
• Reduction of pain during menstruation was noted by all patients of the main group and 15 patients of the comparison group (23.8%)

Dynamic ultrasound monitoring of the endometrium during observation and treatment revealed certain patterns. Baseline monitoring demonstrated similar impairments in endometrial maturation in all groups before treatment.

A significant increase in endometrial thickness in the proliferative phase of the cycle compared to the initial indicators was noted after therapy already at the 3rd month of observation in patients of the main group. While drug therapy had no significant effect.

Evaluation in the secretory phase of the cycle did not reveal significant positive dynamics in patients of the comparison group, while in patients of the main group a significant increase in endometrial parameters was recorded compared to the initial value.

A similar picture was observed in the main group of patients with menstrual dysfunction such as opsomenorrhea, accompanied by anovulation. According to ultrasound data, dynamic folliculogenesis was observed with the appearance of a dominant follicle during the periovulatory period in 85.7% (36 out of 42 people) of patients in the main group. In the comparison group, this indicator was recorded in 39% (8 out of 21) of patients.

A positive effect was observed in relation to the indicators of immunohistochemical examination of endometrial biopsy: the presence of secretory changes in the luteal phase of the cycle and an increase in the endometrial receptor apparatus in 80.9% (34 out of 42) of patients in the main group with CFS. In the comparison group, secretory changes in the endometrium and an increase in the percentage of hormonal receptors were observed in 28.5% (6 out of 21).

Conclusion. The use of FSC in the treatment of correction of menstrual dysfunction such as opsomenorea is a highly effective addition to treatment and helps to avoid complications from drug polypharmacy with hormonal drugs.